Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023.
Espinosa-Gongora C, Berg C, Rehn M, Varg JE, Dillner L, Latorre-Margalef N, Székely AJ, Andersson E, Movert E. Espinosa-Gongora C, et al. Among authors: latorre margalef n. Euro Surveill. 2023 Nov;28(46):2300595. doi: 10.2807/1560-7917.ES.2023.28.46.2300595. Euro Surveill. 2023. PMID: 37971659 Free PMC article.
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; European Primary Care Vaccine Effectiveness Group. Lanièce Delaunay C, et al. Among authors: latorre margalef n. Euro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807/1560-7917.ES.2024.29.13.2300403. Euro Surveill. 2024. PMID: 38551095 Free PMC article.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Laniece Delaunay C, et al. Among authors: latorre margalef n. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258. JAMA Netw Open. 2024. PMID: 38949812 Free PMC article.
A novel SARS-CoV-2 recombinant transmitted from a patient with an acute co-infection.
Dyrdak R, Stamouli S, Ganeshappa Aralaguppe S, Ekman M, Safari H, Berg C, Movert E, Latorre-Margalef N, Andersson E, Gisslén M, Nederby-Öhd J, Leufvén ÅS, Schoenmakers J, Broddesson S, Murrell B, Albert J. Dyrdak R, et al. Among authors: latorre margalef n. Lancet Microbe. 2024 Oct 1:100998. doi: 10.1016/j.lanmic.2024.100998. Online ahead of print. Lancet Microbe. 2024. PMID: 39366391 Free article. No abstract available.
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, Sève N, McKenna A, Meijer A, Rodrigues AP, Martínez-Baz I, Mlinarić I, Latorre-Margalef N, Túri G, Lazăr M, Mazagatos C, Echeverria A, Abela S, Bourgeois M, Machado A, Dürrwald R, Petrović G, Oroszi B, Jancoriene L, Marin A, Husa P, Duffy R, Dijkstra F, Gallardo García V, Goerlitz L, Enouf V, Bennett C, Hooiveld M, Guiomar R, Trobajo-Sanmartín C, Višekruna Vučina V, Samuelsson Hagey T, Lameiras Azevedo AS, Castilla J, Xuereb G, Delaere B, Gómez V, Tolksdorf K, Bacci S, Nicolay N, Kaczmarek M, Rose AM; European IVE group. Maurel M, et al. Among authors: latorre margalef n. Euro Surveill. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089. Euro Surveill. 2024. PMID: 38390651 Free PMC article.
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: latorre margalef n. Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839521 Free PMC article.
Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Martínez-Baz I, Ilić M, Carnahan AS, Mihai ME, Martínez A, Goerlitz L, Enouf V, Horváth JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmartín C, Mlinarić I, Latorre-Margalef N, Ivanciuc A, Lopez A, Dürrwald R, Falchi A, Túri G, Meijer A, Melo A, O'Donnell J, Castilla J, Vučina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, Kissling E; VEBIS study team. Maurel M, et al. Among authors: latorre margalef n. Influenza Other Respir Viruses. 2024 Jan 10;18(1):e13243. doi: 10.1111/irv.13243. eCollection 2024 Jan. Influenza Other Respir Viruses. 2024. PMID: 38204584 Free PMC article.
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: latorre margalef n. Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016/j.vaccine.2024.06.056. Epub 2024 Jul 8. Vaccine. 2024. PMID: 38971666 Free PMC article. No abstract available.
Co-circulation of seasonal influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage viruses with further genetic diversification, EU/EEA, 2022/23 influenza season.
Broberg EK, Svartström O, Riess M, Kraus A, Vukovikj M, Melidou A; Members of the European Reference Laboratory Network for Human Influenza (ERLI-Net); Collaborators. Broberg EK, et al. Euro Surveill. 2024 Sep;29(39):2400020. doi: 10.2807/1560-7917.ES.2024.29.39.2400020. Euro Surveill. 2024. PMID: 39328158 Free PMC article.
41 results